Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$0.99 -2.6%	$0.97	$0.69 ▼ $3.94	$196.93M	0.67	4.91 million shs	4.00 million shs
GNFT GENFIT	$3.61 -6.0%	$4.11	$2.55 ▼ $6.42	$180.50M	1.15	10,553 shs	22,737 shs
INMB INmune Bio	$5.33 -15.1%	$7.42	$4.32 ▼ $11.64	$122.48M	1.55	572,941 shs	59.45 million shs
VNRX VolitionRx	$0.84 -3.5%	$0.56	$0.40 ▼ $0.94	$86.30M	1.07	205,043 shs	139,410 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	0.00%	-7.14%	+16.29%	-31.00%	-55.24%
GNFT GENFIT	0.00%	-7.08%	-17.58%	+5.56%	0.00%
INMB INmune Bio	0.00%	-16.46%	-28.55%	-31.75%	-39.57%
VNRX VolitionRx	0.00%	-8.95%	+66.54%	+46.94%	+38.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	4.2776 of 5 stars	3.4	3.0	3.9	3.3	1.7	0.6
GNFT GENFIT	2.229 of 5 stars	3.5	4.0	0.0	2.7	0.0	0.0
INMB INmune Bio	2.0245 of 5 stars	3.6	0.0	0.0	2.8	1.7	0.6
VNRX VolitionRx	1.6349 of 5 stars	3.5	0.0	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	604.51% Upside
GNFT GENFIT	3.00	Buy	$13.00	260.11% Upside
INMB INmune Bio	3.17	Buy	$22.80	327.77% Upside
VNRX VolitionRx	3.00	Buy	$3.50	317.81% Upside

Current Analyst Ratings Breakdown

Latest VNRX, GNFT, INMB, and ESPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/30/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/8/2025	VNRX VolitionRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$2.50 ➝ $2.50
3/31/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	0.59	$0.02 per share	41.35	($1.97) per share	-0.50
GNFT GENFIT	$76.77M	2.35	$0.07 per share	51.61	$1.50 per share	2.41
INMB INmune Bio	$10K	12,248.34	N/A	N/A	$1.45 per share	3.68
VNRX VolitionRx	$1.31M	65.96	N/A	N/A	($0.11) per share	-7.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/24/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest VNRX, GNFT, INMB, and ESPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.18	0.81
GNFT GENFIT	0.08	1.23	1.23
INMB INmune Bio	N/A	2.64	2.64
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
GNFT GENFIT	2.24%
INMB INmune Bio	12.72%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
GNFT GENFIT	4.20%
INMB INmune Bio	35.70%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
INMB INmune Bio	10	22.98 million	14.78 million	Optionable
VNRX VolitionRx	80	103.02 million	80.80 million	Optionable

VNRX, GNFT, INMB, and ESPR Headlines

Recent News About These Companies

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

Jones Trading Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

June 11, 2025 | msn.com

VolitionRx (NYSE:VNRX) Coverage Initiated at Jones Trading

June 10, 2025 | marketbeat.com

VolitionRx director Guy Innes buys $10,772 in common stock

June 5, 2025 | investing.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

June 5, 2025 | insidertrades.com

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025 | prnewswire.com

VolitionRx Limited (NYSE:VNRX) Director Buys $10,800.00 in Stock

June 4, 2025 | marketbeat.com

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update

May 15, 2025 | prnewswire.com

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update

May 12, 2025 | prnewswire.com

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption

May 7, 2025 | prnewswire.com

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

April 29, 2025 | prnewswire.com

VolitionRx enters new sales agreement, terminates old one

April 24, 2025 | investing.com

VolitionRx initiated with a Buy at H.C. Wainwright

April 8, 2025 | markets.businessinsider.com

HC Wainwright & Co. Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

April 8, 2025 | msn.com

Earnings call transcript: VolitionRx revenue beats forecast in Q4 2024

April 2, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, GNFT, INMB, and ESPR Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$0.99 -0.03 (-2.59%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+1.05%)

As of 06/27/2025 05:44 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

GENFIT NASDAQ:GNFT

$3.81 -0.03 (-0.78%)

As of 06/27/2025 04:00 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

INmune Bio NASDAQ:INMB

$5.33 -0.95 (-15.13%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$5.42 +0.09 (+1.59%)

As of 06/27/2025 08:00 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

VolitionRx NYSE:VNRX

$0.84 -0.03 (-3.49%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.87 +0.03 (+3.98%)

As of 06/27/2025 08:00 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time